Clinical trials: Radiotracer
Healthy Volunteer
A Human Proof of Concept Study for [11C]-RO5011232 as Radiotracer and Study of the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-State in Healthy Volunteers
This open label, non-randomized, parallel group study will evaluate [11C]-RO5011232 as radiotracer for brain mGlu5 receptor occupancy and investigate the binding of RO49917523 to human mGlu5 brain receptor at steady-state in…
- Trial name
- NCT01483469
- Testing
- RO4917523, RO5011232
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Pulmonary Disease, Chronic Obstructive
To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult Males
This will be an open label study conducted at one site. Six healthy male subjects will be enrolled to ensure at least four fully evaluable subjects.
- Trial name
- NCT00599612
- Testing
- GW856553
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostate Cancer, Bone Metastases
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041
A phase1 study to demonstrate [68Ga]P15-041 binding to bone metastases in prostate cancer and determination of human dosimetry.
- Trial name
- NCT02826382
- Testing
- [68Ga]P15-041
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Five Eleven Pharma, Inc.
Ischemic Heart Disease (IHD)
XTR003 PET Radiotracer for the Detection of Viable Myocardium
The study was designed to explore the clinical feasibility of XTR003, a PET myocardial fatty-acid tracer, for the detection of viable myocardium in patients with ischemic heart disease (IHD).
- Trial name
- NCT05885854
- Testing
- XTR003
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sinotau Pharmaceutical Group
Parkinson Disease
A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects
This study evaluates the usefulness of a PET radioligand to estimate the binding on the mGlu4 receptor in the brain. mGlu4 has been proposed as a therapeutic target in Parkinson's disease.
- Trial name
- NCT03826134
- Testing
- [11C]PXT012253
- Where
- Sweden
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Glioblastoma, Brain Tumors
Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma
This clinical trial aims to evaluate the feasibility and safety of early post-operative brain PET-MRI imaging in adult patients who have undergone surgery for suspected glioblastoma.
- Conditions
- Glioblastoma, Brain Tumors, Brain Imaging
- Trial name
- EARLYBRAINPET (NCT07274397)
- Testing
- Early post-operative brain PET-MRI with 18F-DOPA and Gadolinium
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Beta Emitting Accurate Monitored Systems
Healthy Volunteers
FBCx (Alpha-CD) Mechanism of Action Trial
To determine the fat losses in stool associated with alpha-CD use in healthy volunteers, as compared to placebo when consumed with a standardized radiolabeled fatty meal.
- Trial name
- FMAT (NCT02999620)
- Testing
- Alpha-cyclodextrin
- Where
- Australia
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- SFI Research
Rheumatoid Arthritis
Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers
The purpose of this study is to determine how the body breaks down and excretes the investigational drug, AZD5672.
- Trial name
- NCT00711074
- Testing
- AZD5672
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease
Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)
This study will estimate the radiochemical and radiation safety and assess the efficacy of [18F]MK-3328, a novel positron emission tomography (PET) tracer.
- Trial name
- NCT00954538
- Testing
- [18F]MK-3328
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers
Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers
This open-label, radiolabeled, single 100-mg dose study in 6 healthy male volunteers has been designed to further the understanding of human metabolism of lorlatinib.
- Trial name
- NCT03184168
- Testing
- [14C]lorlatinib
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Depressive Disorder
A PET Study in Healthy Volunteers
This will be an open label, non-randomised [11C]PHNO PET study using healthy male volunteers. Each volunteer will undergo 4 [11C]PHNO PET scans to allow for further characterisation of this radioligand and examine the effects of…
- Trial name
- NCT01424449
- Testing
- [11C]PHNO, Aripiprazole
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sleep Initiation and Maintenance Disorders
Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug
The purpose of this study is to define the absorption, breakdown and excretion of a single dose of radiolabelled SB-649868 and its breakdown products by measuring their concentration in blood, urine and faeces over a 7-10 day…
- Trial name
- NCT00520663
- Testing
- 14C-SB649868
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Adult
Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers
This is an open-label, single-center, phase 1 study to further characterize [18F]MODAG-009 in Healthy Volunteers (HV). Approximately 6 participants will be enrolled in this study.
- Trial name
- NCT07617688
- Testing
- [¹⁸F]MODAG-009 PET Imaging
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Hyperhidrosis
Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
The purpose of this study is to characterize the pharmacokinetics (PK), safety and tolerability of topically applied umeclidinium following single dose topical administration.
- Trial name
- NCT01934153
- Testing
- [14C]Umeclidinium 18.5 mg
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteer
A Study of the Pharmacokinetics, Biodistribution and Dosimetry of Granzyme-B Targeted [Cu-64]-Labeled PET Radiotracers in Adult Healthy Volunteers
This is an exploratory clinical study of copper-64 [Cu-64]-labeled granzyme B (GzmB)-targeted compounds for PET/CT imaging. The goal is to determine how GzmB-Targeted [Cu-64]-labeled compounds are distributed in the body by…
- Trial name
- NCT07774650
- Testing
- Granzyme-B targeted [64Cu]-labeled PET radiotracer
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ratio Therapeutics, Inc.
Metastasis to Brain of Unknown Primary
18F ML-10 for Early Detection of Response of Brain Metastases to SRS
The purpose of this study is to evaluate the potential of [18F]-ML-10 to serve as a non-invasive imaging tool for the early detection of apoptosis in brain metastases in response to radiation therapy, in patients subjected to…
- Trial name
- NCT00696943
- Testing
- ([18F]-ML-10)
- Volunteers
- 1 people
- Sponsor
- Aposense Ltd.
Pulmonary Disease, Chronic Obstructive
To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]SB-681323 in Healthy Adult Males
SB-681323 is a p38 MAP kinase inhibitor and is currently under development by GlaxoSmithKline. This will be an open label study conducted at one site.
- Trial name
- NCT00564746
- Testing
- A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Brain Metastases, Solid Tumors
Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.
The purpose of this study is to evaluate the potential of [18F]-ML-10 to serve as an imaging tool for the early detection of response of brain metastases to radiation therapy.
- Trial name
- NCT00805636
- Testing
- 2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10), Stereotactic Radio-Surgery (SRS) therapy, Positron Emission Tomography
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Aposense Ltd.
Schizophrenia
A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls
The primary objective of this study is to compare the effect of two different antipsychotic compounds which are used in the treatment of schizophrenia (paliperidone ER and risperidone) at their target sites in two specific areas…
- Trial name
- NCT00934635
- Testing
- Paliperidone ER, Oral risperidone, PET Scan
- Where
- Germany
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag G.m.b.H
Asthma
Intravenous Microdose Pharmacokinetic (PK) Study With [14C]-GSK2239633
This study is a first administration to man microdose study to describe the pharmacokinetics of GSK2239633.
- Trial name
- NCT01086462
- Testing
- GSK2239633
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline